

OPEN

Updated guidelines to reduce venous thromboembolism in trauma patients: A Western Trauma Association critical decisions algorithm

Eric J. Ley, MD, Carlos V.R. Brown, MD, Ernest E. Moore, MD, Jack A. Sava, MD, Kimberly Peck, MD, David J. Ciesla, MD, Jason L. Sperry, MPH, MD, Anne G. Rizzo, MS, MD, Nelson G. Rosen, MD, Karen J. Brasel, MPH, MD, Rosemary Kozar, MD, PhD, Kenji Inaba, MD, and Matthew J. Martin, MD, Los Angeles, California

CONTINUING MEDICAL EDUCATION CREDIT INFORMATION

Accreditation

The American College of Surgeons is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™

The American College of Surgeons designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Of the AMA PRA Category 1 Credit™ listed above, a maximum of 1 credit meets the requirements for self-assessment.



Objectives

After reading the featured articles published in the *Journal of Trauma and Acute Care Surgery*, participants should be able to demonstrate increased understanding of the material specific to the article. Objectives for each article are featured at the beginning of each article and online. Test questions are at the end of the article, with a critique and specific location in the article referencing the question topic.

Disclosure Information

In accordance with the ACCME Accreditation Criteria, the American College of Surgeons must ensure that anyone in a position to control the content of the educational activity (planners and speakers/authors) has disclosed all relevant financial relationships with any commercial interest. For additional information, please visit the ACCME website (see below for definitions).

Commercial Interest: The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services used on or consumed by patients. Providers of clinical services directly to patients are NOT included in this definition.

Financial Relationships: Relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

Conflict of Interest: Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship.

The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias during the session. Any conflicts noted below have been managed to our

satisfaction. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during the educational activity, please report it on the evaluation.

AUTHORS/ CONTRIBUTORS	NOTHING TO DISCLOSE	DISCLOSURE		
		COMPANY	ROLE	RECEIVED
<i>Ernest Moore</i>		<i>Haemonetics/Instrumentation Laboratory/Stago</i>	<i>PI</i>	<i>Grants</i>
PLANNING COMMITTEE / EDITORIAL COMMITTEE	NOTHING TO DISCLOSE	DISCLOSURE		
		COMPANY	ROLE	RECEIVED
<i>Ernest E. Moore, Editor</i>		<i>Haemonetics</i>	<i>PI</i>	<i>Shared U.S. Patents</i>
		<i>Instrumentation Laboratory</i>	<i>PI</i>	<i>Research Support</i>
		<i>Stago, HumacYTE, Prytime</i>	<i>PI</i>	<i>Research Support</i>
		<i>ThromboTherapeutics</i>	<i>Co-founder</i>	<i>Stock</i>
<i>Associate Editors Ronald V. Maier and Steven Shackford</i>	<i>X</i>			
<i>Editorial Staff and Angela Sautia</i>	<i>X</i>			

Claiming Credit

To claim credit, please visit the AAST website at <http://www.aast.org/> and click on the “e-Learning/MOC” tab. You must read the article, successfully complete the post-test and evaluation. Your CME certificate will be available immediately upon receiving a passing score of 75% or higher on the post-test. Post-tests receiving a score of below 75% will require a retake of the test to receive credit.

Credits can only be claimed online

Cost

For AAST members and *Journal of Trauma and Acute Care Surgery* subscribers there is no charge to participate in this activity. For those who are not a member or subscriber, the cost for each credit is \$25.

Questions

If you have any questions, please contact AAST at 800-789-4006. Paper test and evaluations will not be accepted.

This is a recommended evaluation and management algorithm from the Western Trauma Association (WTA) Algorithms Committee focused on the management of pharmacologic prophylaxis for venous thromboembolism (VTE) prevention in trauma patients. Because there are few related published prospective, randomized clinical trials that have generated class I data on this topic in the trauma population, these recommendations are based primarily on published prospective and retrospective cohort studies, and expert opinion of the WTA members. The final algorithm is the result of an iterative process including an initial internal review and revision by the WTA Algorithm Committee members, and then final revisions based on input during and after presentation of the algorithm to the full WTA membership.

Goals

The algorithm (Fig. 1) and accompanying comments represent a safe and sensible approach to reducing VTE in trauma patients. The aim for this approach was to provide updated guidelines that apply to most patients, most of the time. We recognize that there will be multiple factors that may warrant or require deviation from any single recommended algorithm and that no algorithm can completely replace expert bedside clinical judgment. We encourage institutions and clinicians to use this algorithm as a general framework in the approach to trauma patients and to customize and adapt it to better suit the specifics of that program or location.

Burden of Disease

Venous thromboembolism, including deep vein thrombosis (DVT) and pulmonary embolism (PE), is a potentially preventable complication after trauma. The focus of this algorithm is on optimizing the delivery of pharmacologic prophylaxis to prevent VTE and minimize any associated complications. For those trauma patients diagnosed with a DVT or PE, including distal upper extremity or calf thrombosis, specific treatments are addressed in other guidelines and will not be covered in this algorithm.^{1,2}

Without pharmacologic prophylaxis, a 1994 study determined that the DVT rate was 58% in severely injured trauma

patients who undergo serial impedance plethysmography with lower extremity contrast venography.³ In a landmark, 1996 *New England Journal of Medicine* publication 30 mg of subcutaneous enoxaparin twice daily performed better than 5,000 U of subcutaneous heparin twice daily at reducing DVT in moderate to severely injured trauma patients (31% vs. 44%, $p = 0.04$).⁴ The risk of major bleeding was low regardless of therapy, and importantly, the first dose of pharmacologic prophylaxis was initiated within 36 hours of the injury and continued through all surgical procedures except spinal fixation when a single preoperative dose was held.⁴ This study established that early, uninterrupted enoxaparin was superior to heparin at reducing VTE after trauma. In the last decade, a number of reviews and societal recommendations focused on improving the guidelines to reduce the rate of VTE and related complications after trauma.^{1,2,5–11}

Despite this progress, debate persists regarding optimal dosing and timing of enoxaparin, including when to initiate, hold, and resume it before and after surgery or epidural placement. Trauma patients frequently receive a delayed, suboptimal dose of enoxaparin, which is then held for any potential surgical procedure despite substantial evidence that encourages early, uninterrupted pharmacologic prophylaxis. An updated algorithm on the appropriate management of VTE prophylaxis is therefore indicated.

ALGORITHM

The following lettered sections correspond to the letters identifying specific sections of the algorithm shown in Figure 1. In each section, we provide a brief summary of the important aspects and options that should be considered at that point in the evaluation and management process.

A

This algorithm is designed for adult trauma patients 18 years and older.

Importantly, although younger children have a significantly lower VTE risk, older children and adolescents have a VTE risk that approaches their adult counterparts.¹² Guidance for VTE prophylaxis in children can be found in the joint practice management guideline from the Pediatric Trauma Society and the Eastern Association for the Surgery of Trauma, which recommends, “pharmacologic prophylaxis be considered for children older than 15 years old and in younger postpubertal children with Injury Severity Score (ISS) greater than 25.”¹¹

B

Assessment of VTE risk will assist in determining which patients require pharmacologic prophylaxis.

In general, an ISS of 10 or more suggests that pharmacologic prophylaxis should be initiated as soon as possible, whereas patients with an ISS of less than 10 are at lower VTE risk and may not require pharmacologic prophylaxis.^{13–15} Because ISS is not calculated in real time, the Greenfield Risk Assessment Profile or the Trauma Embolic Scoring System can assist with calculating VTE risk.^{13–15} Patients with spine or pelvic fractures, repair of venous injury, a history of VTE, or inherited clotting disorders have increased VTE risk and should be considered for pharmacologic prophylaxis.^{2,13,14} Among

Submitted: April 24, 2020, Revised: May 26, 2020, Accepted: June 8, 2020, Published online: June 24, 2020.

From the Department of Surgery, Cedars-Sinai Medical Center (E.J.L.), Los Angeles, California; Dell Medical School, University of Texas at Austin (C.V.R.B.), Austin, Texas; Ernest E. Moore Shock Trauma Center (E.E.M.), Denver, Colorado; MedStar Hospital Center (J.A.S.), Washington, District of Columbia; Scripps Mercy Hospital (K.P., M.J.M.), San Diego, California; Morsani College of Medicine (D.J.C.), Tampa, Florida; University of Pittsburgh (J.L.S.), Pittsburgh, Pennsylvania; Inova Trauma Center (A.G.R.), Falls Church, Virginia; Children's Hospital (N.G.R.), Cincinnati, Ohio; Oregon Health and Science University (K.J.B.), Portland, Oregon; University of Maryland School of Medicine (R.K.), Baltimore, Maryland; and Keck School of Medicine (K.I.), Los Angeles, California.

This study was presented at the 50th Annual Western Trauma Association Meeting, February 26, 2020, in Sun Valley, Idaho.

Address for reprints: Eric J. Ley, MD, Department of Surgery, Cedars-Sinai Medical Center, 8635 W 3rd St, Suite 650W, Los Angeles, CA 90048; email: Eric.Ley@cshs.org.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

DOI: 10.1097/TA.0000000000002830




Figure 1. The WTA algorithm for VTE prophylaxis after trauma. Circled letters correspond to sections in the associated article. Algorithm circle-bubbles represent patient criteria; algorithm square-bubbles represent expert recommendations. CrCl, creatinine clearance; Hb, hemoglobin; LMWH, enoxaparin; q8h, every 8 hours; q12h, every 12 hours; UFH, unfractionated heparin.

trauma patients with minor injuries, independent predictors of increased VTE risk are increased age, obesity, and lower extremity fractures; any combination of these three characteristics should encourage initiation of pharmacologic prophylaxis.¹³

C

Patients with minor trauma may not require pharmacologic prophylaxis.

Given the related pain with injection, potential for hematoma at the injection site, cost for the medication, and nursing costs for administration, avoiding pharmacologic prophylaxis may be indicated for select low-risk patients after minor trauma. The Trauma Embolic Scoring System can be used to assess VTE risk, as patients with a low score require no pharmacologic prophylaxis because of their low VTE rate.¹³ Ambulatory patients with minor injuries and short hospital stays may not require pharmacologic prophylaxis. Trauma patients capable of ambulation but confined to bed because of intoxication, restraints, or other reasons should receive pharmacologic prophylaxis. In general, trauma patients who require hospital admission for more than 24 hours require pharmacologic prophylaxis, whereas those hospitalized for less than 24 hours do not. For the patients who do not receive pharmacologic prophylaxis, mechanical prophylaxis and/or aspirin are low cost and low morbidity options, although their benefit is uncertain given the low VTE rate.^{13–16}

D

Appropriate delays in pharmacologic prophylaxis may occur for those patients with an active bleed, coagulopathy, hemodynamic instability, solid organ injury, traumatic brain injury (TBI), or spinal trauma.

Quantifying the risk and benefit of initiating pharmacologic prophylaxis for each patient is a challenge that is best determined by the trauma team at bedside. Detailing every indication where a delay may be indicated is outside the scope of these guidelines; several are described below. However, it is important to note that the guidance in both the literature and clinical practice supports very short delays to the initiation of pharmacologic prophylaxis, even among these cohorts.

Active Bleeding, Coagulopathy, or Hemodynamic Instability

Control of active bleeding is necessary before starting pharmacologic prophylaxis. In the presence of hemodynamic instability, a hemoglobin drop of greater than 2 g/dL in under 12 hours or ongoing blood transfusion is an appropriate indication to delay the initiation of pharmacologic prophylaxis.^{2,4} Systemic coagulopathy was previously proposed as a reason to delay pharmacologic prophylaxis with one study holding pharmacologic prophylaxis for an elevated prothrombin time of more than 3 seconds above control or a platelet count of less than 50,000 per cubic millimeter.⁴ More recent studies indicate that prothrombin time and platelet count are not as reliable at predicting systemic coagulopathy as viscoelastic hemostatic assays, which may demonstrate hypocoagulability and hypercoagulability after trauma.^{2,17–19} The hypocoagulability due to trauma largely resolves within 24 hours, after which hypercoagulability becomes prevalent. In this setting, pharmacologic prophylaxis may be considered after the initial resuscitation is

complete.^{17,20} Deferring the initiation of pharmacologic prophylaxis during trauma-induced coagulopathy is associated with an increased VTE rate such that the initiation of pharmacologic prophylaxis is encouraged if the hypocoagulable state is expected to resolve and there are no signs of ongoing bleeding.¹⁷

Solid Organ Injury

Delays occur in the initiation of pharmacologic prophylaxis for patients with solid organ injury. Several studies indicate that patients with solid organ injury who received early pharmacologic prophylaxis had lower DVT and PE rates without increased risk of failure of nonoperative management, bleeding complications, or mortality; these risks did not increase when pharmacologic prophylaxis was started within 24 hours compared with within 48 hours.^{20–23} Early pharmacologic prophylaxis within 12 to 24 hours appeared to be safe across moderate American Association for the Surgery of Trauma injury grade and type of solid organ injury (liver, spleen, and/or kidney), without an increased risk of bleeding that necessitated intervention or blood transfusion.²¹ Although those with grade IV and V injuries should be approached with caution, pharmacologic prophylaxis may be initiated within 24 hours for most patients with solid organ injury.^{21–23}

Traumatic Brain Injury

Concern for progression of TBI is a common reason for the delay in initiation of pharmacologic prophylaxis. This delay is dependent on the type of TBI; those with “cerebral contusion, localized petechial hemorrhages, or diffuse axonal damage” may safely receive pharmacologic prophylaxis without delay.⁴ When pharmacologic prophylaxis is appropriately delayed, the follow-up computed tomography (CT) after TBI diagnosis is an important indicator for when to initiate pharmacologic prophylaxis.²⁴ For patients with TBI progression on the follow-up CT, exposure to pharmacologic prophylaxis is a predictor for further progression, and it should be held until a follow-up CT demonstrates no progression.²⁴ In contrast, if the follow-up CT demonstrates no TBI progression, then pharmacologic prophylaxis should be initiated.²⁴ Importantly, progression of TBI occurs in about 10% of patients with a stable follow-up CT, regardless of whether pharmacologic prophylaxis is provided or not.²⁴ Those trauma centers that provide pharmacologic prophylaxis within 24 hours after TBI have significantly lower rates of VTE with no difference in rates of late neurosurgical intervention.^{23,25–30} Even in the setting of combat related penetrating TBI, initiating pharmacologic prophylaxis 24 hours after injury for those patients with a stable CT was safe, with similar progression rates regardless of pharmacologic prophylaxis.²⁹ The majority of TBI patients with a stable CT may be initiated on enoxaparin within 24 hours, and nearly all TBI patients should receive pharmacologic prophylaxis within 72 hours of the time of injury.^{23,28,31}

Spinal Trauma

In the absence of pharmacologic prophylaxis, patients who undergo spine surgery or those with spine trauma, fracture, or cord injury have a high incidence of VTE,² and delays longer than 72 hours lead to a substantial increase in the VTE rate.³²

Pharmacologic prophylaxis must be initiated as soon as possible after spine surgery or any spine injury.^{32,33} Regimens that provide pharmacologic prophylaxis preoperatively³⁴ or immediately after operative fixation are considered safe.^{4,34} When a departmental protocol was implemented that required pharmacologic prophylaxis preoperatively or the same day of spine surgery, the VTE rate decreased and the rate of spinal hematoma was unchanged.³⁴ Similarly, pharmacologic prophylaxis initiated within 48 hours of operative fixation of traumatic spine fractures did not increase the risk of bleeding, progression of neurological injury, or postoperative complications including spinal hematoma.^{23,33}

E

Mechanical prophylaxis for moderate to high VTE risk patients is encouraged regardless of concurrent pharmacologic prophylaxis.

For patients who are not started immediately on pharmacologic prophylaxis, mechanical prophylaxis with intermittent pneumatic compression and mobilization, when possible, should be encouraged. Intermittent pneumatic compression lowers the DVT incidence if no pharmacologic prophylaxis is initiated and therefore is recommended for patients with a contraindication to pharmacologic prophylaxis.^{2,35,36} In contrast, the addition of intermittent pneumatic compression in critically ill patients who received pharmacologic prophylaxis did not lead to a reduction in the DVT rate, although the study had a low DVT rate and only 8% of the population were trauma patients.¹⁶ Combining mechanical prophylaxis with pharmacologic prophylaxis is therefore encouraged for moderate to high VTE risk patients in part because those who received the combination had a lower incidence of symptomatic PE.³⁵ Compression stockings do not appear to reduce the VTE rate in the presence of pharmacologic prophylaxis,¹⁶ but thigh high compression stockings may provide a benefit to those trauma patients who cannot be started on pharmacologic prophylaxis.²

Mobility is also an important component for VTE prevention, as early mobility leads to a reduction in VTE.³⁷ A mobility protocol is safe in trauma patients and may reduce patient deconditioning besides decreasing the rate of VTE.³⁷ Prolonged maintenance of spinal precautions is associated with an increased DVT rate and should be avoided to allow early mobility.³⁸

F

Weekly venous compression duplex should be considered in patients at high VTE risk who cannot be started or maintained on pharmacologic prophylaxis.

Although debate persists, routine surveillance with venous compression duplex is not indicated or feasible for all trauma patients.² Routine surveillance duplex after trauma does not decrease the risk of PE or fatal PE, and false-positive results lead to unnecessary therapeutic anticoagulation.² In trauma patients at low VTE risk, the high cost and low yield of acute, clinically relevant findings suggest that the practice may be avoided. Some institutions advocate for routine surveillance in low-risk trauma patients to identify both acute and preexisting DVT, which may help identify and treat the related complications such as venous insufficiency, venous stasis ulcers, or pain with ambulation.³⁹ For trauma patients at high VTE risk, routine

surveillance duplex is associated with a reduced PE rate.³⁹ The Greenfield Risk Assessment Profile can identify which trauma patients may benefit from routine surveillance.^{14,39} Weekly duplex scanning may be particularly beneficial in high VTE risk patients who cannot be started or maintained on pharmacologic prophylaxis. Whatever the institutional guidelines, identification of DVT should not be a hospital-reported outcome. Institutions that routinely screen all trauma patients have higher rates of DVT, and those centers with comprehensive quality improvement efforts that do not routinely screen will also have higher DVT rates because of a lower threshold for ordering a venous compression duplex.

G

Pharmacologic prophylaxis must be initiated as soon as possible and for most trauma patients may be initiated within 24 hours.

When high VTE risk trauma patients who receive enoxaparin within 24 hours of admission are compared with those who receive only mechanical prophylaxis, minor and major bleeding events do not differ.⁴⁰ As detailed in section E, appropriate delays may occur in the initiation of pharmacologic prophylaxis because of active bleeding, coagulopathy, hemodynamic instability, solid organ injury, TBI, or spinal trauma. In most cases, pharmacologic prophylaxis may be started in less than 24 hours, and in almost every case, pharmacologic prophylaxis may be started in less than 72 hours.

Pharmacologic prophylaxis is often held because of pending surgery despite the evidence that it may be initiated before most surgical procedures.^{4,41-43} Trauma patients who require an operation are unique in that their first operation may occur within minutes of arrival or days into the hospitalization. Increasingly, pharmacologic prophylaxis is delayed or skipped for pending surgery, which leads to an increased VTE rate.⁴⁰ Preoperative dosing of pharmacologic prophylaxis is not unique to trauma. In other patient populations at high risk for VTE, the use of preoperative pharmacologic prophylaxis decreased the DVT rate without increasing the complication rate.^{41,42} Guidelines for perioperative care in gynecologic/oncology recommend, "Prophylaxis should be initiated pre-operatively and continued post-operatively."⁴⁴ Patients who underwent elective hip surgery who received low molecular weight heparin approximately 6 hours before surgery had a lower rate of proximal DVT without increasing major, minor, or trivial bleeding rates.⁴³ This benefit was not observed when low molecular weight heparin was provided 12 hours or more preoperatively.⁴³ We believe that the common and somewhat reflexive process of withholding pharmacologic prophylaxis for 12 to 24 hours before planned surgical procedures is almost always unnecessary and will result in an increased VTE risk without an accompanying decrease in the risk of bleeding events.

H

After deciding to start pharmacologic prophylaxis, the specific anticoagulant and initial dose should be determined for each patient. Enoxaparin is the recommended choice for most trauma patients with higher doses now considered the standard of care.

The preferred agent for pharmacologic prophylaxis is the low molecular weight heparin enoxaparin because of its

increased bioavailability, longer plasma-half life, and more predictable pharmacokinetics and pharmacodynamics compared with unfractionated heparin.^{4,45} Enoxaparin interacts less with platelets, which may reduce bleeding complications compared with unfractionated heparin; has a lower incidence of heparin-induced thrombocytopenia (HIT); and does not have the associated osteoporosis observed with heparin treatment.⁴⁶

When choosing the initial dose, 40 mg of enoxaparin twice daily should be considered the standard for most trauma patients, as 30 mg twice daily frequently results in inadequate pharmacologic prophylaxis.^{47–55} Therefore, patients 18 to 65 years with weight of more than 50 kg and a creatinine clearance of more than 60 mg/dL should be started on 40 mg of enoxaparin twice daily, as this dose is safe and reduces the VTE rate.^{47–55} Patients who are older than 65 years, weigh less than 50 kg, or who have a creatinine clearance of 30 to 60 mg/dL should continue to receive initial dosing at 30 mg of enoxaparin twice daily.

The initial enoxaparin dose for trauma patients with a normal creatine clearance may also be based on weight. Options include 0.5 mg/kg twice daily,^{51,52} 0.6 mg/kg twice daily,⁵³ or 30 mg for 50 to 60 kg patients, 40 mg for 61 to 99 kg patients, and 50 mg for patients greater than 100 kg.⁵⁴ Patients who are initiated on higher doses of enoxaparin based upon weight should be monitored by anti-Xa levels because of the fluctuations in creatinine clearance after trauma that might lead to changes in the enoxaparin dose.⁵⁰

Although enoxaparin is preferable to heparin for pharmacologic prophylaxis, some institutions continue to dose unfractionated heparin at 5,000 U three times daily based in part on a randomized trial that suggested that this regimen might be noninferior and cost-effective compared with 30 mg of enoxaparin twice daily.⁵⁶ This practice should be reconsidered as the trial was underpowered because of an assumed DVT rate of 44% for unfractionated heparin versus 31% for enoxaparin, and a 10% noninferiority margin for the power calculation. The actual difference in the VTE rate was 3.1%, which favored enoxaparin without reaching significance (unfractionated heparin, 8.2% vs. enoxaparin, 5.1%; $p = 0.2$).^{45,56} In addition, the study was not powered to detect a difference in the rate of PE or HIT, both of which impact the complication rate and health care costs.^{45,57} More recently, 30 mg of enoxaparin twice daily was established as superior to 5000 U of unfractionated heparin three times daily at the prevention of VTE and PE.⁴⁵

Unfractionated Heparin for Renal Failure

Quantifying the risk and benefit of the type and initial dose of pharmacologic prophylaxis for each patient is a challenge best determined by the trauma team at bedside. As noted, 40 mg of enoxaparin twice daily is the recommended initial pharmacologic prophylaxis for most trauma patients. Detailing every indication where an alternative therapeutic or dose may be indicated is outside the scope of these guidelines; several are described below.

In the presence of end-stage renal disease or a creatinine clearance of <30 mg/dL, subcutaneous unfractionated heparin at 5000 U every 8 hours may be initiated.² Because enoxaparin is excreted by the kidneys, its administration to patients with

renal failure may lead to increased bleeding complications and should be avoided.² Enoxaparin has not been Food and Drug Administration approved for use in dialysis patients. Providing lower enoxaparin doses in the setting of a creatinine clearance of <30 mg/dL while closely monitoring anti-Xa levels may be possible in the future, but additional research is necessary before this recommendation can be made. In most other settings, enoxaparin is preferable to unfractionated heparin, as enoxaparin leads to lower VTE rates without increased bleeding complications.^{4,45}

Brain and Spine Trauma

For TBI patients, enoxaparin is associated with less VTE and higher survival than unfractionated heparin with no difference in the progression of brain lesions, regardless if the dose was delivered in less than 24 hours after admission, between 24 to 48 hours, or after 48 hours.²⁶ Similarly, those patients with spine trauma should preferentially receive early enoxaparin.^{32,33} Patients with brain and spine trauma should be initiated on 30 mg of enoxaparin twice daily and considered for dose adjustment by anti-Xa level.^{4,47}

Pregnant Patients

Pregnant patients require specific dose recommendations for pharmacologic prophylaxis after trauma because of the progressive hypercoagulability,⁵⁸ as well as the increase in renal clearance and weight changes that occur over the course of pregnancy.⁵⁹ These variables generally require higher enoxaparin doses with more frequent dosing. Neither unfractionated heparin nor enoxaparin crosses the placenta, and both are considered safe to use in pregnancy.^{58–60} As such, during an admission for trauma, pregnant patients should receive 30 mg of enoxaparin twice daily titrated by anti-Xa levels targeting a peak range of 0.2 to 0.4 IU/mL or a trough range of 0.1 to 0.2 IU/mL. For pregnant patients who weigh more than 90 kg, initiating 40 mg of enoxaparin twice daily is recommended with similar anti-Xa level titration.^{58–60}

Isolated Orthopedic Injuries and Direct Oral Anticoagulants

Pharmacologic prophylaxis with direct oral anticoagulants (DOACs) or aspirin should not be a primary choice for pharmacologic prophylaxis for most trauma patients because of the lack of related clinical trials. The use of DOACs or aspirin may be considered in the setting of isolated orthopedic injuries, but only if the patient declines injection with enoxaparin or unfractionated heparin.^{5,61–66} Two DOACs are approved for pharmacologic prophylaxis after elective orthopedic surgery, 10 mg of rivaroxaban once daily, and 2.5 mg of apixaban twice daily, both which are direct oral factor Xa inhibitors. Most orthopedic trials that compare rivaroxaban or apixaban to enoxaparin demonstrate that DOACs have equal to better VTE rates with similar to higher bleeding rates.^{62–64,66–68} In contrast, other analyses conclude that enoxaparin has a lower VTE rate⁶⁹ and a lower bleeding rate.⁷⁰ Because only retrospective analyses have examined the use of DOACs for pharmacologic prophylaxis after trauma, randomized controlled trials are necessary before DOACs becoming a primary agent for trauma patients.^{66,71,72}

The use of low dose aspirin may also be considered for pharmacologic prophylaxis in trauma patients with isolated orthopedic injuries who decline injection.^{2,5,69,73} For those trauma patients started on a DOAC for pharmacologic prophylaxis, aspirin may replace the DOAC after 5 days with similar prevention of VTE.⁷⁴

I

Many trauma patients require dose adjustment after initiating enoxaparin.

Because of the variations in renal clearance, weight, bioavailability, and coagulation cascade, monitoring enoxaparin by anti-Xa levels is necessary. In one series, 84% of trauma patients required doses of 40 mg or more, and 18% required doses of 50 mg or more.⁴⁷ Adjusting enoxaparin by anti-Xa peak or trough levels appears to lower the VTE rate without increasing bleeding complications in moderate to severely injured patients, trauma patients who require ICU admission, burn injuries, and surgical oncology patients.^{47-49,75} Although some debate exists on the appropriate target for anti-Xa levels, consensus suggests targeting 0.2 to 0.4 IU/mL for peak levels or 0.1 to 0.2 IU/mL for trough levels.^{47-50,55,75,76} Anti-Xa monitoring should also be considered for those patients who receive weight-based enoxaparin.^{50,53,76}

Although thromboelastography (TEG) has not been validated for monitoring pharmacologic prophylaxis, TEG with platelet mapping may assist with monitoring platelet inhibition. A randomized trial that used TEG as an adjunct to identify inadequate enoxaparin doses did not observe lower rates of VTE with the TEG-guided enoxaparin dosing.⁷⁷ In contrast, TEG with platelet mapping may help determine if a hypercoagulability is due to platelet function, which encourages the addition of aspirin to the pharmacologic prophylaxis regimen.⁷⁸ If aspirin is added, the initial recommended dose is 81 mg daily with the possibility of increasing the dose to 325 mg daily depending on subsequent TEG with platelet mapping results.^{18,19}

J

The continuous, uninterrupted dosing of pharmacologic prophylaxis should be the standard for most trauma patients throughout their hospital stay.

Although the safety and benefit of uninterrupted pharmacologic prophylaxis were established decades ago, more than half of trauma patients encounter interruptions.^{79,80} A direct correlation is observed between the number of missed doses and DVT risk such that patients who miss two to four doses have 8.5 times higher DVT risk compared with those with no missed doses.⁸⁰ For TBI patients who are started on pharmacologic prophylaxis, interrupted dosing causes an approximately 600% increase in the VTE rate.⁸¹

The following are common reasons for missed pharmacologic prophylaxis: pending invasive procedure (41.6%), none (27.1%), patient was absent from the room (11.7%), concern for bleeding (12.1%), epidural catheter removal (5.9%), and physician/nursing error (1.6%).⁸⁰ When holding pharmacologic prophylaxis, the rate of bleeding with pharmacologic prophylaxis is no different than without it.⁴⁰ If nonfatal VTE events are compared with nonfatal bleeding complications, the risk/benefit ratio favors continuing pharmacologic prophylaxis.⁸²

Every effort should focus on continuing pharmacologic prophylaxis without interruption. The appropriate indications for holding or altering pharmacologic prophylaxis include acute thrombus, craniotomy, spinal surgery, epidural placement, or HIT, and these are expanded upon below.

Acute Thrombus

Although routine VTE surveillance is not indicated for all trauma patients,² weekly duplex scanning may be warranted in those at high VTE risk.³⁹ Selective venous compression duplex should be performed promptly for symptomatic evidence of DVT such as unexpected leg swelling or pain.⁶ For those trauma patients with significant injuries and gaps in pharmacologic prophylaxis, weekly venous compression duplex may be considered.³⁹ If a DVT or PE is identified, then therapeutic anticoagulation is necessary per current guidelines, and if it is contraindicated, then an inferior vena cava (IVC) filter should be considered as detailed in section K.¹

Pending Surgery

As discussed in section G, routinely holding pharmacologic prophylaxis because of pending surgery is only indicated, with few exceptions, for brain or spine surgery.⁴ Given the delays and cancellations of cases that may occur during trauma patient care, holding pharmacologic prophylaxis preoperatively can cause days of missed pharmacologic prophylaxis. Preoperative pharmacologic prophylaxis is safe for trauma patients^{2,4} and leads to a lower VTE rate.⁴³ The preoperative administration of pharmacologic prophylaxis is also encouraged for surgical patients in other specialties who have a high VTE risk and leads to a lower DVT rate without increasing the complication rate.^{4,41-43} The lower VTE rate is lost if pharmacologic prophylaxis is provided more than 12 hours preoperatively.⁴³

Epidural Catheter

Epidural catheters reduce morbidity and mortality in trauma patients sustaining chest injuries and are often a component of multimodal pain strategies. Patients who require an epidural catheter increasingly have interruptions in pharmacologic prophylaxis⁸³ such that epidural catheter placement is now associated with an increased VTE rate^{84,85} whereas previously this was not the case.⁸⁶ Regional Anesthesia Guidelines recommend a 12-hour interval between enoxaparin dose and epidural placement/removal followed by a 4-hour to 12-hour interval before resumption.^{9,10} If enoxaparin is scheduled at 10 AM and 10 PM, the morning dose may be held for 10 AM epidural catheter placement/removal to allow for the necessary 12-hour interval without pharmacological prophylaxis. At 10 PM, the scheduled enoxaparin dosing may resume, so only one dose is missed. If higher doses of enoxaparin are required for pharmacologic prophylaxis, Regional Anesthesia Guidelines recommend a 24-hour interval for therapeutic enoxaparin before epidural catheter placement/removal followed by a 4-hour to 12-hour interval before resumption,^{9,10} indicating that, at most, two doses of enoxaparin should be missed for any enoxaparin therapy. Anti-Xa-guided enoxaparin doses are encouraged with limited interruption to reverse the higher VTE rate associated with epidural use.^{84,85} For unfractionated heparin, a 4 to

6-hour interval is recommended before epidural placement/removal followed by a 1-hour interval before unfractionated heparin is resumed, which allows for uninterrupted dosing.

Heparin-Induced Thrombocytopenia

Selective platelet monitoring should be considered for those trauma patients who receive pharmacologic prophylaxis because of the risk of heparin-induced thrombocytopenia (HIT). Platelet monitoring is recommended for patients who are considered high risk for HIT approximately every 3 days from day 4 to day 14 or until pharmacologic prophylaxis is stopped.⁷ Trauma patients who are exposed only to enoxaparin may be considered low risk for HIT and may not require routine platelet monitoring, as the rate of clinical HIT was 2.7% with prophylactic heparin compared with 0% with prophylactic enoxaparin.^{7,87} The clinical diagnosis of HIT may be predicted by assigning scores that include thrombocytopenia, timing, thrombosis, and alternative causes.^{7,88,89} Once diagnosed, the heparin anticoagulants must be replaced with nonheparin anticoagulants, such as the direct thrombin inhibitor argatroban, which can create challenges for trauma patients suspicious for HIT because of the irreversible nature of these anticoagulants and the difficulties with dosing and maintaining their therapeutic levels.^{7,88,89}

K

Inferior vena cava filters may be considered in the setting of proximal DVT or PE when there is a contraindication to appropriate therapeutic anticoagulation.

The use of IVC filters is variable among trauma centers although their placement is decreasing without a documented change in PE rates, so prophylactic placement is not recommended.⁹⁰ In a randomized controlled trial of high VTE risk trauma patients who were unable to receive pharmacologic prophylaxis during the first 72 hours of admission, a prophylactic IVC filter did not lower the incidence of PE or mortality, which established the lack of utility of early prophylactic placement of an IVC filter in this population.⁹¹ The placement of an IVC filter does not impact mortality regardless of whether a DVT is present or absent.^{92,93} While consensus guidelines provide conflicting recommendations and most studies have been observational, among patients diagnosed with an acute proximal DVT or PE who cannot receive adequate therapeutic anticoagulation, an IVC filter should be considered to reduce the rate of recurrent PE without altering the mortality rate.⁹⁴

L

Trauma patients with TBI, orthopedic or spine injuries, and those who undergo major surgery are at particular VTE risk and should be considered for postdischarge pharmacologic prophylaxis.

Pharmacologic prophylaxis after discharge for high VTE risk trauma patients is supported by evidence that demonstrates the practice is efficacious, safe, and cost-effective and may be considered for patients with TBI, orthopedic or spine injuries, and those who undergo major surgery.^{2,95–98} The highest VTE risk occurs during the first 3 months after injury with approximately 1 year required until the VTE rate returns to that of the general population.^{95,97} Venous thromboembolism-related readmissions account for 1.2% of 1-year trauma readmissions at a cost of US \$250 million annually.⁹⁹

Postdischarge pharmacologic prophylaxis with enoxaparin is efficacious, associated with a low rate of clinically relevant bleeding complications, and is cost-effective in patients at high VTE risk.^{2,96} The introduction of postdischarge pharmacologic prophylaxis following abdominal or pelvic surgery for malignancy or inflammatory bowel disease was associated with a decrease in VTE events.⁹⁸ Because the optimal postdischarge dose and duration of enoxaparin after trauma are not well studied, doses more than 30 mg twice daily should be avoided, and the duration of pharmacologic prophylaxis may be considered for up to 4 weeks after the date of admission.² For those who undergo major orthopedic surgery, pharmacologic prophylaxis may be extended up to 35 days from the date of surgery.⁵ Aspirin may be initiated for postdischarge pharmacologic prophylaxis for high VTE risk trauma patients, as it has been shown to be as effective as enoxaparin with less bleeding complications and better postdischarge adherence, and is not limited by the constraints of insurance oversight.^{98,100} Direct oral anticoagulants may also be considered for postdischarge pharmacologic prophylaxis after isolated orthopedic injury.⁷⁴

SUMMARY AND CONCLUSIONS

This algorithm was designed to provide comprehensive and clear guidance aimed at reducing the VTE rate after trauma. Although there are multiple factors that will lead to deviations from the presented algorithm, most trauma patients should be initiated on early and higher doses of enoxaparin that often should be adjusted by anti-Xa levels. For most trauma patients, pharmacologic prophylaxis should continue uninterrupted throughout the hospital stay and at times after discharge. Avoiding preventable and non-evidence-based delays to the initiation and missed doses of pharmacologic prophylaxis should be a best-practice focus of all trauma centers, and it has clearly been associated with decreased rates of VTE events.

AUTHORSHIP

All authors contributed in the conception and design. E.J.L. contributed in the data acquisition. All authors contributed in the data interpretation. E.J.L., C.V.R.B., E.E.M., and M.J.M. contributed in the article preparation. All authors contributed in the critical revisions.

DISCLOSURE

The authors declare no conflicts of interest. The results and opinions expressed in this article are those of the authors and do not reflect the opinions or official policy of any of the listed affiliated institutions, the United States Army, or the Department of Defense (if military coauthors).

REFERENCES

1. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(Suppl 2):e419S–e496S.
2. Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, Samama CM. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(Suppl 2):e227S–e277S.

3. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A prospective study of venous thromboembolism after major trauma. *N Engl J Med.* 1994; 331(24):1601–1606.
4. Geerts WH, Jay RM, Code KI, Chen E, Szalai JP, Saibil EA, Hamilton PA. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. *N Engl J Med.* 1996;335(10):701–707.
5. Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, Ortel TL, Pauker SG, Colwell CW Jr. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* 2012;141(Suppl 2):e278S–e325S.
6. Bates SM, Jaeschke R, Stevens SM, et al. Diagnosis of DVT: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* 2012;141(Suppl 2):e351S–e418S.
7. Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, Crowther M. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* 2012;141(Suppl 2):e495S–e530S.
8. Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. *Blood Adv.* 2019;3(23):3898–3944.
9. Horlocker TT, Vandermeulen E, Kopp SL, Gogarten W, Lefert LR, Benzon HT. Regional Anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine evidence-based guidelines (fourth edition). *Reg Anesth Pain Med.* 2018;43(3):263–309.
10. Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Llau JV, Samama CM, European Society of Anaesthesiology. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. *Eur J Anaesthesiol.* 2010;27(12):999–1015.
11. Mahajerin A, Petty JK, Hanson SJ, Thompson AJ, O'Brien SH, Streck CJ, Petrillo TM, Faustino EV. Prophylaxis against venous thromboembolism in pediatric trauma: a practice management guideline from the Eastern Association for the Surgery of Trauma and the Pediatric Trauma Society. *J Trauma Acute Care Surg.* 2017;82(3):627–636.
12. Liras IN, Rahbar E, Harting MT, Holcomb JB, Cotton BA. When children become adults and adults become most hypercoagulable after trauma: an assessment of admission hypercoagulability by rapid thrombelastography and venous thromboembolic risk. *J Trauma Acute Care Surg.* 2016;80(5): 778–782.
13. Rogers FB, Shackford SR, Horst MA, Miller JA, Wu D, Bradburn E, Rogers A, Krasne M. Determining venous thromboembolic risk assessment for patients with trauma: the Trauma Embolic Scoring System. *J Trauma Acute Care Surg.* 2012;73(2):511–515.
14. Meizoso JP, Karcutskie CA4th, Ray JJ, Ruiz X, Ginzburg E, Namias N, Schulman CI, Proctor KG. A simplified stratification system for venous thromboembolism risk in severely injured trauma patients. *J Surg Res.* 2017;207:138–144.
15. Greenfield LJ, Proctor MC, Rodriguez JL, Luchette FA, Cipolle MD, Cho J. Posttrauma thromboembolism prophylaxis. *J Trauma.* 1997;42(1): 100–103.
16. Arabi YM, Al-Hameed F, Burns KEA, et al. Adjunctive intermittent pneumatic compression for venous thromboprophylaxis. *N Engl J Med.* 2019; 380(14):1305–1315.
17. Sumislawski JJ, Kornblith LZ, Conroy AS, Callcut RA, Cohen MJ. Dynamic coagulability after injury: is delaying venous thromboembolism chemoprophylaxis worth the wait? *J Trauma Acute Care Surg.* 2018;85(5): 907–914.
18. Kornblith LZ, Kutcher ME, Redick BJ, Calfee CS, Vilardi RF, Cohen MJ. Fibrinogen and platelet contributions to clot formation: implications for trauma resuscitation and thromboprophylaxis. *J Trauma Acute Care Surg.* 2014;76(2):255–256; discussion 262–3.
19. Harr JN, Moore EE, Chin TL, Ghasabayan A, Gonzalez E, Wohlauer MV, Banerjee A, Silliman CC, Sauaia A. Platelets are dominant contributors to hypercoagulability after injury. *J Trauma Acute Care Surg.* 2013;74(3): 756–762; discussion 762–5.
20. Coleman JR, Kay AB, Moore EE, Moore HB, Gonzalez E, Majercik S, Cohen MJ, White T, Pieracci FM. It's sooner than you think: blunt solid organ injury patients are already hypercoagulable upon hospital admission — results of a bi-institutional, prospective study. *Am J Surg.* 2019;218(6): 1065–1073.
21. Schellenberg M, Inaba K, Biswas S, Heindel P, Benjamin E, Strumwasser A, Matsushima K, Lam L, Demetriades D. When is it safe to start VTE prophylaxis after blunt solid organ injury? A prospective study from a level I trauma center. *World J Surg.* 2019;43(11):2797–2803.
22. Skarupa D, Hanna K, Zeeshan M, Madbak F, Hamidi M, Haddadin Z, Northcutt A, Gries L, Kulvatunyou N, Joseph B. Is early chemical thromboprophylaxis in patients with solid organ injury a solid decision? *J Trauma Acute Care Surg.* 2019;87(5):1104–1112.
23. Regner JL, Shaver CN, SWSC Multicenter Trials Group. Determining the impact of culture on venous thromboembolism prevention in trauma patients: a Southwestern Surgical Congress Multicenter trial. *Am J Surg.* 2019;217(6):1030–1036.
24. Levy AS, Salottolo K, Bar-Or R, Offner P, Mains C, Sullivan M, Bar-Or D. Pharmacologic thromboprophylaxis is a risk factor for hemorrhage progression in a subset of patients with traumatic brain injury. *J Trauma.* 2010; 68(4):886–894.
25. Byrne JP, Mason SA, Gomez D, Hoeft C, Subacius H, Xiong W, Neal M, Pirouzmand F, Nathens AB. Timing of pharmacologic venous thromboembolism prophylaxis in severe traumatic brain injury: a propensity-matched cohort study. *J Am Coll Surg.* 2016;223(4):621–631.e5.
26. Benjamin E, Recinos G, Aiolfi A, Inaba K, Demetriades D. Pharmacological thromboembolic prophylaxis in traumatic brain injuries: low molecular weight heparin is superior to unfractionated heparin. *Ann Surg.* 2017; 266(3):463–469.
27. Störmann P, Osinloye W, Freiman TM, Seifert V, Marzi I, Lustenberger T. Early chemical thromboprophylaxis does not increase the risk of intracranial hematoma progression in patients with isolated severe traumatic brain injury. *World J Surg.* 2019;43(11):2804–2811.
28. Phelan HA, Wolf SE, Norwood SH, et al. A randomized, double-blinded, placebo-controlled pilot trial of anticoagulation in low-risk traumatic brain injury: the Delayed Versus Early Enoxaparin Prophylaxis I (DEEP I) study. *J Trauma Acute Care Surg.* 2012;73(6):1434–1441.
29. Meyer RM, Larkin MB, Szuflita NS, Neal CJ, Tomlin JM, Armonda RA, Bailey JA, Bell RS. Early venous thromboembolism chemoprophylaxis in combat-related penetrating brain injury. *J Neurosurg.* 2017;126(4): 1047–1055.
30. Spano PJ2nd, Shaikh S, Boneva D, Hai S, McKenney M, Elkbuli A. Anti-coagulant chemoprophylaxis in patients with traumatic brain injuries: a systematic review. *J Trauma Acute Care Surg.* 2020;88(3):454–460.
31. Norwood SH, Berne JD, Rowe SA, Villarreal DH, Ledlie JT. Early venous thromboembolism prophylaxis with enoxaparin in patients with blunt traumatic brain injury. *J Trauma.* 2008;65(5):1021–1026; discussion 1026–7.
32. Christie S, Thibault-Halman G, Casha S. Acute pharmacological DVT prophylaxis after spinal cord injury. *J Neurotrauma.* 2011;28(8):1509–1514.
33. Kim DY, Kobayashi L, Chang D, Fortlage D, Coimbra R. Early pharmacological venous thromboembolism prophylaxis is safe after operative fixation of traumatic spine fractures. *Spine.* 2015;40(5):299–304.
34. Cox JB, Weaver KJ, Neal DW, Jacob RP, Hoh DJ. Decreased incidence of venous thromboembolism after spine surgery with early multimodal prophylaxis: clinical article. *J Neurosurg Spine.* 2014;21(4):677–684.
35. Kakkos SK, Caprini JA, Geroulakos G, Nicolaidis AN, Stansby G, Reddy DJ, Ntouvas I. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism. *Cochrane Database Syst Rev.* 2016;9:CD005258.
36. Dennis M, Sandercock P, Graham C, Forbes J, CLOTS (Clots in legs Or sTockings after stroke) trials collaboration, Smith J. The Clots in Legs Or sTockings after Stroke (CLOTS) 3 trial: a randomised controlled trial to determine whether or not intermittent pneumatic compression reduces the risk of post-stroke deep vein thrombosis and to estimate its cost-effectiveness. *Health Technol Assess.* 2015;19(76):1–90.
37. Booth K, Rivet J, Flichi R, Harvey E, Hamill M, Hundley D, Holland K, Hubbard S, Trivedi A, Collier B. Progressive mobility protocol reduces venous thromboembolism rate in trauma intensive care patients: a quality improvement project. *J Trauma Nurs.* 2016;23(5):284–289.

38. MacCallum KP, Kalata S, Darcy D, Parsikia A, Chao E, Stone ME, Teperman S, Reddy SH. Prolonged use of spinal precautions is associated with increased morbidity in the trauma patient. *Injury*. 2020;51(2):317–321.
39. Allen CJ, Murray CR, Meizoso JP, Ginzburg E, Schulman CI, Lineen EB, Namias N, Proctor KG. Surveillance and early management of deep vein thrombosis decreases rate of pulmonary embolism in high-risk trauma patients. *J Am Coll Surg*. 2016;222(1):65–72.
40. Ginzburg E, Cohn SM, Lopez J, Jackowski J, Brown M, Hameed SM, Miami Deep Vein Thrombosis Study Group. Randomized clinical trial of intermittent pneumatic compression and low molecular weight heparin in trauma. *Br J Surg*. 2003;90(11):1338–1344.
41. Whitworth JM, Schneider KE, Frederick PJ, Finan MA, Reed E, Fauci JM, Straughn JM Jr., Rocconi RP. Double prophylaxis for deep venous thrombosis in patients with gynecologic oncology who are undergoing laparotomy: does preoperative anticoagulation matter? *Int J Gynecol Cancer*. 2011;21(6):1131–1134.
42. Selby LV, Sovel M, Sjoberg DD, et al, MSKCC VTE Task Force. Preoperative chemoprophylaxis is safe in major oncology operations and effective at preventing venous thromboembolism. *J Am Coll Surg*. 2016;222(2):129–137.
43. Hull RD, Pineo GF, Stein PD, et al. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. *Arch Intern Med*. 2001;161(16):1952–1960.
44. Nelson G, Bakkum-Gamez J, Kalogera E, et al. Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations—2019 update. *Int J Gynecol Cancer*. 2019;29(4):651–668.
45. Jacobs BN, Cain-Nielsen AH, Jakubus JL, Mikhail JN, Fath JJ, Regenbogen SE, Hemmila MR. Unfractionated heparin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in trauma. *J Trauma Acute Care Surg*. 2017;83(1):151–158.
46. Fareed J, Hoppensteadt D, Walenga J, Iqbal O, Ma Q, Jeske W, Sheikh T. Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice. *Clin Pharmacokinet*. 2003;42(12):1043–1057.
47. Ko A, Harada MY, Barmparas G, Chung K, Mason R, Yim DA, Dhillon N, Margulies DR, Gewertz BL, Ley EJ. Association between enoxaparin dosage adjusted by anti-factor Xa trough level and clinically evident venous thromboembolism after trauma. *JAMA Surg*. 2016;151(11):1006–1013.
48. Singer GA, Riggi G, Karcutskie CA, Vaghaiwalla TM, Lieberman HM, Ginzburg E, Namias N, Lineen EB. Anti-Xa-guided enoxaparin thromboprophylaxis reduces rate of deep venous thromboembolism in high-risk trauma patients. *J Trauma Acute Care Surg*. 2016;81(6):1101–1108.
49. Lin H, Faraklas I, Saffle J, Cochran A. Enoxaparin dose adjustment is associated with low incidence of venous thromboembolic events in acute burn patients. *J Trauma*. 2011;71(6):1557–1561.
50. Rodier SG, Bukur M, Moore S, Frangos SG, Tandon M, DiMaggio CJ, Ayoung-Chee P, Marshall GT. Weight-based enoxaparin with anti-factor Xa assay-based dose adjustment for venous thromboembolic event prophylaxis in adult trauma patients results in improved prophylactic range targeting. *Eur J Trauma Emerg Surg*. 2019. doi:10.1007/s00068-019-01215-0 Epub ahead of print.
51. Walker CK, Sandmann EA, Horyna TJ, Gales MA. Increased enoxaparin dosing for venous thromboembolism prophylaxis in general trauma patients. *Ann Pharmacother*. 2017;51(4):323–331.
52. Bickford A, Majercik S, Bledsoe J, Smith K, Johnston R, Dickerson J, White T. Weight-based enoxaparin dosing for venous thromboembolism prophylaxis in the obese trauma patient. *Am J Surg*. 2013;206(6):847–851; discussion 851–2.
53. Nunez JM, Becher RD, Rebo GJ, Farrah JP, Borgerding EM, Stirparo JJ, Lauer C, Kilgo P, Miller PR. Prospective evaluation of weight-based prophylactic enoxaparin dosing in critically ill trauma patients: adequacy of AntiXa levels is improved. *Am Surg*. 2015;81(6):605–609.
54. Berndtson AE, Costantini TW, Lane J, Box K, Coimbra R. If some is good, more is better: an enoxaparin dosing strategy to improve pharmacologic venous thromboembolism prophylaxis. *J Trauma Acute Care Surg*. 2016;81(6):1095–1100.
55. Cronin BJ, Godat LN, Berndtson AE, Pham A, Kolan S, Box K, Lee JG, Costantini TW. Anti-Xa guided enoxaparin dose adjustment improves pharmacologic deep venous thrombosis prophylaxis in burn patients. *Burns*. 2019;45(4):818–824.
56. Olson EJ, Bandle J, Calvo RY, et al. Heparin versus enoxaparin for prevention of venous thromboembolism after trauma: a randomized noninferiority trial. *J Trauma Acute Care Surg*. 2015;79(6):961–968; discussion 968–9.
57. Byrne JP, Geerts W, Mason SA, Gomez D, Hoeft C, Murphy R, Neal M, Nathens AB. Effectiveness of low-molecular-weight heparin versus unfractionated heparin to prevent pulmonary embolism following major trauma: a propensity-matched analysis. *J Trauma Acute Care Surg*. 2017;82(2):252–262.
58. Duhl AJ, Paidas MJ, Ural SH, et al, Pregnancy and Thrombosis Working Group. Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. *Am J Obstet Gynecol*. 2007;197(5):457.e1–457.e21.
59. Eubanks AA, Deering SH, Thiel LM. Risk assessment and treatment guide for obstetric thromboprophylaxis: comprehensive review of current guidelines. *Am J Perinatol*. 2019;36(2):130–135.
60. Lamont MC, McDermott C, Thomson AJ, Greer IA. United Kingdom recommendations for obstetric venous thromboembolism prophylaxis: evidence and rationale. *Semin Perinatol*. 2019;43(4):222–228.
61. Beyer-Westendorf J, Mouret P, Turpie AG. Rivaroxaban for venous thromboembolism prevention after major orthopedic surgery: translating trial data into routine clinical practice. *Orthop Res Rev*. 2017;9:1–11.
62. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. *N Engl J Med*. 2008;358(26):2765–2775.
63. Turpie AGG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. *Lancet*. 2009;373(9676):1673–1680.
64. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM, ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. *N Engl J Med*. 2010;363(26):2487–2498.
65. Blin P, Samama C-M, Sautet A, et al. Comparative effectiveness of direct oral anticoagulants versus low-molecular weight heparins for the prevention of venous thromboembolism after total hip or knee replacement: a nationwide database cohort study. *Pharmacol Res*. 2019;141:201–207.
66. Kingdon LK, Miller EM, Savage SA. The utility of rivaroxaban as primary venous thromboprophylaxis in an adult trauma population. *J Surg Res*. 2019;244:509–515.
67. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. *N Engl J Med*. 2009;361(6):594–604.
68. Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, Weitz JJ, ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. *N Engl J Med*. 2011;365(23):2167–2177.
69. Agaba P, Kildow BJ, Dhotar H, Seyler TM, Bolognesi M. Comparison of postoperative complications after total hip arthroplasty among patients receiving aspirin, enoxaparin, warfarin, and factor Xa inhibitors. *J Orthop*. 2017;14(4):537–543.
70. Goh EL, Gurung PK, Ma S, Pilpel T, Dale JH, Kannan A, Anand S. Direct oral anticoagulants in the prevention of venous thromboembolism following surgery for hip fracture in older adults: a population-based cohort study. *Geriatr Orthop Surg Rehabil*. 2020;11:2151459319897520.
71. Hamidi M, Zeeshan M, Kulvatunyou N, Mitra HS, Hanna K, Tang A, Northcutt A, O'Keefe T, Joseph B. Operative spinal trauma: thromboprophylaxis with low molecular weight heparin or a direct oral anticoagulant. *J Thromb Haemost*. 2019;17(6):925–933.
72. Hamidi M, Zeeshan M, Sakran JV, Kulvatunyou N, O'Keefe T, Northcutt A, Zakaria ER, Tang A, Joseph B. Direct oral anticoagulants vs low-molecular-weight heparin for thromboprophylaxis in nonoperative pelvic fractures. *J Am Coll Surg*. 2019;228(1):89–97.
73. Matharu GS, Kunutsor SK, Judge A, Blom AW, Whitehouse MR. Clinical effectiveness and safety of aspirin for venous thromboembolism prophylaxis after total hip and knee replacement: a systematic review and meta-analysis of randomized clinical trials. *JAMA Intern Med*. 2020;180:376–384.

74. Anderson DR, Dunbar M, Murnaghan J, et al. Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty. *N Engl J Med*. 2018;378(8):699–707.
75. Kramme K, Sarraf P, Munene G. Prophylactic enoxaparin adjusted by anti-factor Xa peak levels compared with recommended thromboprophylaxis and rates of clinically evident venous thromboembolism in surgical oncology patients. *J Am Coll Surg*. 2020;230(3):314–321.
76. Celik F, Huitema ADR, Hooijberg JH, van de Laar AWJM, Brandjes DPM, Gerdes VEA. Fixed-dose enoxaparin after bariatric surgery: the influence of body weight on peak anti-Xa levels. *Obes Surg*. 2015;25(4):628–634.
77. Connelly CR, Van PY, Hart KD, et al. Thrombelastography-based dosing of enoxaparin for thromboprophylaxis in trauma and surgical patients: a randomized clinical trial. *JAMA Surg*. 2016;151(10):e162069.
78. Brill JB, Calvo RY, Wallace JD, Lewis PR, Bansal V, Sise MJ, Shackford SR. Aspirin as added prophylaxis for deep vein thrombosis in trauma: a retrospective case-control study. *J Trauma Acute Care Surg*. 2016;80(4):625–630.
79. Ramanathan R, Gu Z, Limkemann AJ, Chandrasekhar S, Rensing E, Mays C, Duane TM. Association between interruptions in chemical prophylaxis and VTE formation. *Am Surg*. 2015;81(7):732–737.
80. Louis SG, Sato M, Geraci T, Anderson R, Cho SD, Van PY, Barton JS, Riha GM, Underwood S, Differding J, Watters JM, Schreiber MA. Correlation of missed doses of enoxaparin with increased incidence of deep vein thrombosis in trauma and general surgery patients. *JAMA Surg*. 2014;149(4):365–370.
81. Salottolo K, Offner P, Levy AS, Mains CW, Slone DS, Bar-Or D. Interrupted pharmacologic thromboprophylaxis increases venous thromboembolism in traumatic brain injury. *J Trauma*. 2011;70(1):19–24; discussion 25–6.
82. Nathens AB, McMurray MK, Cuschieri J, et al. The practice of venous thromboembolism prophylaxis in the major trauma patient. *J Trauma*. 2007;62(3):557–562; discussion 562–3.
83. Stone AB, Grant MC, Lau BD, Hobson DB, Streiff MB, Haut ER, Wu CL, Wick EC. Thoracic epidural anesthesia and prophylactic three times daily unfractionated heparin within an enhanced recovery after surgery pathway for colorectal surgery. *Reg Anesth Pain Med*. 2017;42(2):197–203.
84. Vella MA, Dumas RP, Chreiman K, Wasser T, Smith BP, Reilly PM, Seamon MJ, Shiroff A. Epidural catheters are associated with an increased risk of venous thromboembolism in trauma. *J Thromb Thrombolysis*. 2020;49:420–425.
85. Zaw AA, Murry J, Hoang D, Chen K, Louy C, Bloom MB, Melo N, Alban RE, Margulies DR, Ley EJ. Epidural analgesia after rib fractures. *Am Surg*. 2015;81(10):950–954.
86. Gage A, Rivara F, Wang J, Jurkovich GJ, Arbabi S. The effect of epidural placement in patients after blunt thoracic trauma. *J Trauma Acute Care Surg*. 2014;76(1):39–45; discussion 45–6.
87. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. *N Engl J Med*. 1995;332(20):1330–1335.
88. Berry C, Tcherniantchouk O, Ley EJ, Salim A, Mirocha J, Martin-Stone S, Stolpner D, Margulies DR. Overdiagnosis of heparin-induced thrombocytopenia in surgical ICU patients. *J Am Coll Surg*. 2011;213(1):10–17; discussion 17–18.
89. Harada MY, Hoang DM, Zaw AA, Murry JS, Volod O, Sun BJ, Nuño M, Mason R, Margulies DR, Ley EJ. Overtreatment of heparin-induced thrombocytopenia in the surgical ICU. *Crit Care Med*. 2017;45(1):28–34.
90. Cook AD, Gross BW, Osler TM, Rittenhouse KJ, Bradburn EH, Shackford SR, Rogers FB. Vena cava filter use in trauma and rates of pulmonary embolism, 2003–2015. *JAMA Surg*. 2017;152(8):724–732.
91. Ho KM, Rao S, Honeybul S, et al. A multicenter trial of vena cava filters in severely injured patients. *N Engl J Med*. 2019;381(4):328–337.
92. Sarosiek S, Rybin D, Weinberg J, Burke PA, Kasotakis G, Sloan JM. Association between inferior vena cava filter insertion in trauma patients and in-hospital and overall mortality. *JAMA Surg*. 2017;152(1):75–81.
93. Hemmila MR, Osborne NH, Henke PK, Kepros JP, Patel SG, Cain-Nielsen AH, Birkmeyer NJ. Prophylactic inferior vena cava filter placement does not result in a survival benefit for trauma patients. *Ann Surg*. 2015;262(4):577–585.
94. Bickdeli B, Chatterjee S, Desai NR, Kirtane AJ, Desai MM, Bracken MB, Spencer FA, Monreal M, Goldhaber SZ, Krumholz HM. Inferior vena cava filters to prevent pulmonary embolism: systematic review and meta-analysis. *J Am Coll Cardiol*. 2017;70(13):1587–1597.
95. Godat LN, Kobayashi L, Chang DC, Coimbra R. Can we ever stop worrying about venous thromboembolism after trauma? *J Trauma Acute Care Surg*. 2015;78(3):475–480; discussion 480–1.
96. Huo MH, Muntz J. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review. *Clin Ther*. 2009;31(6):1129–1141.
97. Olufajo OA, Yorkgitis BK, Cooper Z, Rios-Diaz A, Metcalfe D, Havens JM, Kelly E, Haider AH, Gates JD, Salim A. How long should we fear? Long-term risk of venous thromboembolism in patients with traumatic brain injury. *J Trauma Acute Care Surg*. 2016;81(1):71–78.
98. Najjar PA, Madenci AL, Zogg CK, et al. Implementation of a comprehensive post-discharge venous thromboembolism prophylaxis program for abdominal and pelvic surgery patients. *J Am Coll Surg*. 2016;223(6):804–813.
99. Rattan R, Parreco J, Eidelson SA, Gold J, Dharmaraja A, Zakrisson TL, Dante Yeh D, Ginzburg E, Namias N. Hidden burden of venous thromboembolism after trauma: a national analysis. *J Trauma Acute Care Surg*. 2018;85(5):899–906.
100. Haac BE, Van Besien R, O'Hara NN, et al. Post-discharge adherence with venous thromboembolism prophylaxis after orthopedic trauma: results from a randomized controlled trial of aspirin versus low molecular weight heparin. *J Trauma Acute Care Surg*. 2018;84(4):564–574.